Literature DB >> 8656673

Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia.

S Ogawa1, M Kurokawa, T Tanaka, K Tanaka, A Hangaishi, K Mitani, N Kamada, Y Yazaki, H Hirai.   

Abstract

Evi-1 is a transforming gene originally identified in a common integration site of murine leukemia retrovirus and mapped in human chromosome 3q26. It is not normally expressed in either human or murine hematopoietic cells, but is overexpressed in retrovirus-induced murine myeloid leukemias as well as human myeloid leukemias with 3q26 abnormalities, and thus thought to be responsible for both human and murine leukemogenesis. In this study, possible involvement of the Evi-1 gene in human leukemias was evaluated by Northern blot analysis in a total of 73 patients with various types of leukemias. We found that increased expression of the Evi-1 gene was most frequently observed in patients with CML in blastic crisis. It was found in 10 of 14 (71.0%) samples from CML in blastic crisis, three of 15 (20.0%) from acute myelocytic leukemia, three of 11 (27.3%) from MDS-derived leukemia, and one of 11 (9.1%) from acute lymphoblastic leukemia. Among 18 patients showing increased Evi-1 expression, none of 17 informative patients showed cytogenetic abnormalities involving 3q26. In addition, Southern blot analysis revealed neither amplification nor rearrangements of the Evi-1 gene in 11 Evi-1-positive patients whose DNA samples were available. Our results suggest that increased expression of the Evi-1 gene may play an important role in development of human leukemias, especially in progression from chronic phase to blastic crisis of CML even without 3q26 abnormalities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8656673

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  23 in total

1.  Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors.

Authors:  Emilie A Bard-Chapeau; Justin Jeyakani; Chung H Kok; Julius Muller; Belinda Q Chua; Jayantha Gunaratne; Arsen Batagov; Piroon Jenjaroenpun; Vladimir A Kuznetsov; Chia-Lin Wei; Richard J D'Andrea; Guillaume Bourque; Nancy A Jenkins; Neal G Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-19       Impact factor: 11.205

2.  Chronic neutrophilic leukemia with overexpression of EVI-1, and concurrent CSF3R and SETBP1 mutations: A case report.

Authors:  Otgonbat Altangerel; Shannan Cao; Juanxia Meng; Peng Liu; Gong Haiyan; Yuanfu Xu; Mingfeng Zhao
Journal:  Oncol Lett       Date:  2015-07-13       Impact factor: 2.967

3.  Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase.

Authors:  Kadin Karakaya; Friederike Herbst; Claudia Ball; Hanno Glimm; Alwin Krämer; Harald Löffler
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

4.  EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation.

Authors:  Emilie A Bard-Chapeau; Jayantha Gunaratne; Pankaj Kumar; Belinda Q Chua; Julius Muller; Frederic A Bard; Walter Blackstock; Neal G Copeland; Nancy A Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

5.  The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.

Authors:  M Kurokawa; K Mitani; T Yamagata; T Takahashi; K Izutsu; S Ogawa; T Moriguchi; E Nishida; Y Yazaki; H Hirai
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

6.  Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 chromosomal translocation in hematologic malignancies.

Authors:  Mei Huang; Chunrui Li; Huang Liang; Jianfeng Zhou; Jinniu Deng; Wenli Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

7.  Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells.

Authors:  Yang Du; Nancy A Jenkins; Neal G Copeland
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

Review 8.  Role of transforming growth factor-beta in hematologic malignancies.

Authors:  Mei Dong; Gerard C Blobe
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

9.  Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.

Authors:  A Sayadi; J Jeyakani; S H Seet; C-L Wei; G Bourque; F A Bard; N A Jenkins; N G Copeland; E A Bard-Chapeau
Journal:  Oncogene       Date:  2015-08-03       Impact factor: 9.867

10.  Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.

Authors:  Wei Wang; Jorge E Cortes; Pei Lin; Michael W Beaty; Di Ai; Hesham M Amin; Timothy J McDonnell; Chi Young Ok; Hagop M Kantarjian; L Jeffrey Medeiros; Shimin Hu
Journal:  Blood       Date:  2015-08-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.